| Daniel Pettit, DO | |
|
4350 Jackson Rd Ste 200, Ann Arbor, MI 48103-1889 | |
| (734) 761-2581 | |
| (734) 761-9540 |
| Full Name | Daniel Pettit |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 15 Years |
| Location | 4350 Jackson Rd Ste 200, Ann Arbor, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285868588 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 02003818A (Indiana) | Secondary |
| 207Q00000X | Family Medicine | 5101024423 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Joseph Mercy Hospital | Ann arbor, MI | Hospital |
| St Joseph Mercy Chelsea | Chelsea, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Iha Health Services Corporation | 2466351440 | 911 |
News Archive
For women who have multiple miscarriages, the pain of repeated loss is often compounded by another reality. The causes behind miscarriage are complex and often difficult to identify, and even those conditions and associations proposed as causes are poorly understood.
Seattle Genetics, Inc. today announced that Health Canada has issued a Notice of Compliance with conditions (NOC/c), authorizing marketing of ADCETRIS for two lymphoma indications.
GlaxoSmithKline and XenoPort, Inc. today announced top-line results from a Phase II clinical trial evaluating GSK1838262/XP13512 (gabapentin enacarbil) in adult patients with neuropathic pain associated with post-herpetic neuralgia (PHN) who have had a history of inadequate response to gabapentin doses of 1800 mg/day or higher.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, announced today that it has established a Scientific Advisory Board to help advance the company's research and clinical studies in type 1 diabetes.
› Verified 2 days ago
| Entity Name | Iha Health Services Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457408965 PECOS PAC ID: 2466351440 Enrollment ID: O20040108000355 |
News Archive
For women who have multiple miscarriages, the pain of repeated loss is often compounded by another reality. The causes behind miscarriage are complex and often difficult to identify, and even those conditions and associations proposed as causes are poorly understood.
Seattle Genetics, Inc. today announced that Health Canada has issued a Notice of Compliance with conditions (NOC/c), authorizing marketing of ADCETRIS for two lymphoma indications.
GlaxoSmithKline and XenoPort, Inc. today announced top-line results from a Phase II clinical trial evaluating GSK1838262/XP13512 (gabapentin enacarbil) in adult patients with neuropathic pain associated with post-herpetic neuralgia (PHN) who have had a history of inadequate response to gabapentin doses of 1800 mg/day or higher.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, announced today that it has established a Scientific Advisory Board to help advance the company's research and clinical studies in type 1 diabetes.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel Pettit, DO 24 Frank Lloyd Wright Dr Lbby J2000, Ann Arbor, MI 48105-9484 Ph: (734) 747-6766 | Daniel Pettit, DO 4350 Jackson Rd Ste 200, Ann Arbor, MI 48103-1889 Ph: (734) 761-2581 |
News Archive
For women who have multiple miscarriages, the pain of repeated loss is often compounded by another reality. The causes behind miscarriage are complex and often difficult to identify, and even those conditions and associations proposed as causes are poorly understood.
Seattle Genetics, Inc. today announced that Health Canada has issued a Notice of Compliance with conditions (NOC/c), authorizing marketing of ADCETRIS for two lymphoma indications.
GlaxoSmithKline and XenoPort, Inc. today announced top-line results from a Phase II clinical trial evaluating GSK1838262/XP13512 (gabapentin enacarbil) in adult patients with neuropathic pain associated with post-herpetic neuralgia (PHN) who have had a history of inadequate response to gabapentin doses of 1800 mg/day or higher.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, announced today that it has established a Scientific Advisory Board to help advance the company's research and clinical studies in type 1 diabetes.
› Verified 2 days ago
Ketti Sophia Petersen, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Dr. James Robert Neuenschwander, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3131 Professional Dr, Ann Arbor, MI 48104 Phone: 734-995-3200 Fax: 734-995-4254 | |
Ms. Natasha Kristine Nguyen, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1540 E Hospital Dr Spc 5718, Ann Arbor, MI 48109 Phone: 734-936-9777 Fax: 734-936-6897 | |
Ms. Alicia J Cohen, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1801 Briarwood Circle, Ann Arbor, MI 48108 Phone: 734-998-7390 | |
Dana Marie O'neill, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4200 Whitehall Dr Ste 130, Ann Arbor, MI 48105 Phone: 734-995-0303 Fax: 734-995-0425 | |
Karl Thomas Rew, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 24 Frank Lloyd Wright, Lobby H, Ann Arbor, MI 48105 Phone: 734-647-5640 | |
Dr. Noshir Yazdi Amaria, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 207 Fletcher St, Ann Arbor, MI 48109 Phone: 734-764-8320 |